GGrantIndex
Sort

8,912 grants matching sars cov 2

tRNA-derived RNA Fragments and their Role in Nasal SARS-CoV-2 Infection

$240,000
Xiaoyong Bao · University Of Texas Med Br Galveston · R21 · FY2022 · AI

RAPID: Design, Fabrication, and Testing a Prototype of Heatable Face Mask for Preventing Respiratory Diseases Contracted through Airborne

$239,990
Vesselin N Shanov · University Of Cincinnati Main Campus · · FY2020 · ENG

Origin and host adaptation of the novel canine coronavirus (CCoV-HuPn-2018) isolated from a human pneumonia patient

$239,852
Anastasia Nickolaevna Vlasova · Ohio State University · R21 · FY2024 · AI

Immune evasion by SARS-CoV-2: the role of HLA class I

$239,850
Marlene Bouvier · University Of Illinois At Chicago · R21 · FY2023 · AI

Development of MMP14-laden exosomes as a novel anti-SARS-CoV-2 therapy

$239,850
Kyuyeon Han · University Of Illinois At Chicago · R21 · FY2024 · AI

Identifying and evaluating prevention strategies for COVID-19 in correctional facilities

$239,627
Margaret Lind · Boston University Medical Campus · R00 · FY2025 · AI

The impact of the COVID-19 pandemic on adolescent drinking in a longitudinal cohort spanning 21 U.S. cities

$239,625
William Ellerbe Pelham III · University Of California, San Diego · R21 · FY2023 · AA

Evaluation of Artemisia as an Effective Combination Therapy Against SARS-CoV-2 Infection

$239,586
Joshua Kellogg · Pennsylvania State University, The · R21 · FY2022 · AI

Assessing the efficacy of BCG vaccination in a pre-clinical model of SARS-CoV-2 infection

$239,521
Alan Sher · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Assessing the Risk of SARS-CoV-2 Remdesivir Resistance

$239,500
Judd F Hultquist · Northwestern University At Chicago · R21 · FY2021 · AI

Rewiring SARS-CoV Genome Organization and Pathogenesis

$239,406
Ralph S Baric · Univ Of North Carolina Chapel Hill · P01 · FY2006 · AI

Creation and Validation of cell-based screening systems for SARS-CoV-2 drug targets

$239,250
Thomas Melendy · State University Of New York At Buffalo · R21 · FY2022 · AI

Elucidating the role of SERINC5 in SARS-CoV-2 infection

$239,250
Spyridon Stavrou · State University Of New York At Buffalo · R21 · FY2022 · AI

Interactions of SARS-CoV-2 N-protein

$239,250
Peter Schuck · National Institute Of Biomedical Imaging And Bioengineering · ZIA · FY2020 · EB

NMR-based discovery of influenza hemagglutinin probes

$239,250
Michael S. Caffrey · University Of Illinois At Chicago · R21 · FY2012 · AI

RAPID: PHYSICS OF CORONAVIRUS SARS-COV-2 SURVIVAL OUTSIDE A HOST AND IMPLICATIONS FOR SEASONAL DEPENDENCE OF COVID-19 OUTBREAKS

$238,975
Michael D Vershinin · University Of Utah · · FY2020 · MPS

Transforming Urine Output Tracking in Hospitalized Heart Failure Patients

$238,943
Lawrence Anthony David · Duke University · R21 · FY2024 · HL

RAPID: Bioinformatic Search for Epitope-based Molecular Mimicry in the SARS-CoV-2 Virus using Chameleon

$238,798
Giri Narasimhan · Florida International University · · FY2020 · CSE

MOMI Clinical Core

$238,522
Andrea Goldberg Edlow · Massachusetts Institute Of Technology · U19 · FY2025 · AI

SARS-CoV-2 infection of non-human primates

$238,324
Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

ENDOTHELIAL AUTONOMOUS MECHANISMS OF EXACERBATED OUTCOMES IN MICE WITH AUTOIMMUNE DEMYELINATING DISEASE AND SARS-COV-2

$238,258
University Of Illinois · · FY2021 · Defense Health Agency

Viral exposure signatures may define individuals vulnerable for COVID-19

$238,096
Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Identifying the targets of virus-induced PARPs during SARS-CoV-2 infection

$238,025
Anthony R Fehr · University Of Kansas Lawrence · R21 · FY2023 · AI

Tomorrow's Science Today: Preparing for the Next Pandemic

$237,833
Tim M. Herman · 3d Molecular Designs · R25 · FY2023 · GM

Infectious Influence: Using fate mapping to determine the impact of viral infection sites on Alzheimer's disease initiation

$237,829
E. Ashley Moseman · Duke University · R21 · FY2021 · AG